Drugmaker Bristol-Myers Squibb Co will globally develop, make and sell a therapy being tested by New York’s Rockefeller University to treat COVID-19, the company said on Wednesday.
The university has developed a combination monoclonal antibody treatment that neutralizes SARS-CoV-2, the virus responsible for COVID-19.
Pre-clinical data showed the combination therapy could enable effective treatment against multiple variants of the virus, the company said.
An early-stage trial was started by the university in mid-January to assess the safety of the therapy.
The university is entitled to receive royalty payments on future sales under the terms of agreement.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News, Breaking News and Coronavirus News here
Comments
0 comment